TCT 2025
Join us at TCT in San Francisco, October 25-28, to discover new waves of innovation and help us celebrate one million patients treated with Shockwave Intravascular Lithotripsy (IVL).
Wave After Wave of Innovation
Join us in San Francisco as we unveil the next era of Coronary IVL, plus exciting new safety data and a sneak peek at how we’re making even bigger waves as part of Johnson & Johnson MedTech.
- Meet our next-generation Coronary IVL catheter and dive into the latest safety and efficacy data on our proven mechanism of action (MOA) at our expert-led symposium
- Help us celebrate a shocking milestone — treating one million patients — at a special event featuring Dr. Nick West, Shockwave Medical CMO, and co-founder, John Adams
- Continue your learning with scientific sessions of interest
Symposium | Introducing the Next Era of Coronary IVL: An Aero-volution in Calcium Modification
Sunday, October 26, 2025 | 12:30-1:30pm PT
Join us as we spark discussion and share findings that will energize your daily practice.
Learning objectives:
- Meet the newest device in our portfolio and see results from the first cases
- Discover more about our unique MOA’s proven crack record
- Explore pooled safety data from our Shockwave clinical studies, as well as EMPOWER CAD and BALI
Featured Shockwave Symposium Speakers
This section contains attributions including profile pictures, titles, descriptions, and Twitter handles.
-
Dr. Ziad Ali, ModeratorSt Francis Hospital & Heart Center Roslyn, Roslyn, New York -
Prof. James Spratt, SpokespersonSt. George’s University NHS Trust, London, United Kingdom
-
Dr. Yousif Ahmad, SpokespersonUSCF Health, San Francisco, CA
-
Dr. Rhian Davies, SpokespersonWellSpan Health, York, PA
-
Dr. Matthew Price, SpokespersonScripps Clinic, La Jolla, CA
Special Event | Teamwork Makes the Treatment Work: Thanks for Impacting the Lives of 1M Patients with IVL
Sunday, October 26, 2025 | Museum of Modern Art (MoMA) | 7:00pm – 9:30pm PT
Dr. Nick West, CMO of Shockwave Medical, and John Adams, co-founder of Shockwave Medical, reflect on our wave-making IVL journey from invention to treating one million patients worldwide.
Join us to commemorate this incredible milestone, recognize the physicians who made it possible, and look ahead at the innovations we’re developing now that will generate the future of IVL tomorrow.
Scientific Sessions of Interest
Accordion Section
5:15PM PT | Shockwave Balloon vs. Atherectomy With Rotablation in Calcified Coronary Artery Lesions: Primary Results of the SONAR Trial
Presenter: Johan R. Bennett
Location: Moscone North | Exhibition Level | Hall E | Presentation Theater 4
9:30AM PT | Intravascular Lithotripsy in Left Main Stem Percutaneous Coronary Intervention
Presenter: Claudia Cosgrove
Location: Moscone South | Exhibition Level | Halls B-C | Station 3
9:40AM PT | Primary Results of the Mini-C First-in-Human Study of a Novel Non-Balloon-Based Coronary Intravascular Lithotripsy System
Presenter: Julian Strange
Location: Moscone Center | Moscone South | Exhibition Level | Halls B-C | Station 3
12:10PM PT | Intravascular Lithotripsy in Real-World Calcified Coronary Lesions: Insights from the GISE Shockcalcium Registry
Presenter: Giulia Nardi
Location: Moscone South | Exhibition Level | Halls B-C | Station 3
2:00PM PT | The EMPOWER CAD Study of Women with Calcified Coronary Arteries: Insights into the Use of Optical Coherence Tomography with Intravascular Lithotripsy
Presenter: Yousif Ahmed
Location: Moscone South | Exhibition Level | Halls B-C | Station 3
3:30PM PT | Sex Specific Outcomes of Treating Patients with Refractory Angina with the Coronary Sinus Reducer: One-year outcomes from the REDUCER-I Registry
Presenter: Eva Buschmann
Location: | Moscone South | Exhibition Level | Halls B-C | Station 5
5:40PM PT | Gender Differences in Outcomes of Intravascular Lithotripsy versus Mechanical Atherectomy for Severely Calcified Coronary Lesions: A ROLLING STONE Registry Sub-Analysis
Presenter: Marco Pavani
Location: Moscone South | Exhibition Level | Halls B-C | Station 3
11:20AM PT | How effectively calcium fractures post intravascular lithotripsy can be identified on intravascular imaging?
Presenter: Sandeep Basavarajaiah
Location: Moscone South | Exhibition Level | Halls B-C | Station 3
COSIRA II Clinical Trial
COSIRA II is a multicenter, randomized, double-blind, sham-controlled trial designed to evaluate Shockwave Reducer, a novel therapeutic option for treating refractory angina pectoris. Learn more about this exciting trial, including target patients and participating sites in the U.S. and United Kingdom.1
Physicians featured are paid consultants of Shockwave Medical.
Caution: In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use. The Reducer is subject of Investigational testing and is being studied in the COSIRA-II trial in Canada.
1 Shockwave Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on warnings, precautions and adverse events: ifu.sw-reducer.com